176 related articles for article (PubMed ID: 30619250)
1. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
2. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.
Cheedarla N; Precilla KL; Babu H; Vijayan KKV; Ashokkumar M; Chandrasekaran P; Kailasam N; Sundaramurthi JC; Swaminathan S; Buddolla V; Vaniambadi SK; Ramanathan VD; Hanna LE
Sci Rep; 2017 Apr; 7():46557. PubMed ID: 28436427
[TBL] [Abstract][Full Text] [Related]
3. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
4. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
5. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
6. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
[TBL] [Abstract][Full Text] [Related]
8. Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.
Cheedarla N; Hemalatha B; Anangi B; Muthuramalingam K; Selvachithiram M; Sathyamurthi P; Kailasam N; Varadarajan R; Swaminathan S; Tripathy SP; Vaniambadi SK; Vadakkupattu DR; Hanna LE
Front Immunol; 2018; 9():618. PubMed ID: 29662494
[TBL] [Abstract][Full Text] [Related]
9. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
11. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
13. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
14. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
16. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
Andrabi R; Bala M; Kumar R; Wig N; Hazarika A; Luthra K
PLoS One; 2012; 7(8):e43704. PubMed ID: 22952740
[TBL] [Abstract][Full Text] [Related]
18. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.
Wibmer CK; Bhiman JN; Gray ES; Tumba N; Abdool Karim SS; Williamson C; Morris L; Moore PL
PLoS Pathog; 2013 Oct; 9(10):e1003738. PubMed ID: 24204277
[TBL] [Abstract][Full Text] [Related]
19. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
20. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
Ferreira CB; Merino-Mansilla A; Llano A; Pérez I; Crespo I; Llinas L; Garcia F; Gatell JM; Yuste E; Sanchez-Merino V
J Virol; 2013 Nov; 87(22):12227-36. PubMed ID: 24006439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
